Guidance

1 Guidance

1 Guidance

1.1 Current evidence on the safety and efficacy of interstitial laser therapy for fibroadenomas of the breast does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research.

1.2 Clinicians wishing to undertake interstitial laser therapy for fibroadenomas of the breast should take the following actions.

  • Inform the clinical governance leads in their Trusts.

  • Audit and review all patients having interstitial laser therapy for fibroadenomas of the breast.

  • Ensure that patients understand the benign nature of fibroadenomas, and that watchful waiting is an option. Patients should be provided with clear written information and use of NICE's information for the public is recommended.

1.3 This procedure should be carried out only within specialist breast services.

1.4 Publication of safety and efficacy outcomes will be useful. The Institute may review the procedure upon publication of further evidence.